Peter Kabos, MD
Associate Professor, Medicine-Medical Oncology

Photo
Medical School:
  • MD, Comenius University School of Medicine (1998)
Internship:
  • University of Southern California/California Hospital Medical Center (Los Angeles) Program (2004)
Residency:
  • University of Southern California/California Hospital Medical Center (Los Angeles) Program, Internal Medicine (2006)
Fellowships:
  • University of Colorado (University Hospital) Program, Hematology and Oncology (2009)
Languages: English
Department: Medicine-Medical Oncology

Publications

  • Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 Jan;21(1):48-57. PubMed PMID: 34728571
  • Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JR. Evaluating anthracycline? ?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022 Jan;191(2):389-399. PubMed PMID: 34705147
  • Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2021 Dec 2. [Epub ahead of print] PubMed PMID: 34856027
  • Márquez-Ortiz RA, Contreras-Zárate MJ, Tesic V, Alvarez-Eraso KLF, Kwak G, Littrell Z, Costello JC, Sreekanth V, Ormond DR, Karam SD, Kabos P, Cittelly DM. IL13Ra2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases. Clin Cancer Res. 2021 Nov 15;27(22):6209-6221. PubMed PMID: 34544797
  • Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Apr 16;7(1):44. PubMed PMID: 33863913
  • Schreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, Kabos P, Diamond JR. Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. Front Oncol. 2021;11:640690. PubMed PMID: 33816286
  • Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun;187(3):883-891. PubMed PMID: 33625615
  • Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021 Apr 20;39(12):1360-1370. PubMed PMID: 33513026
  • Sakamoto MR, Eguchi M, Azelby CM, Diamond JR, Fisher CM, Borges VF, Bradley CJ, Kabos P. New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer. J Natl Compr Canc Netw. 2021 Jan 6;19(1):29-38. PubMed PMID: 33406490
  • Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater. 2021 Apr;20(4):548-559. PubMed PMID: 33257795
  • Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor breast cancer. Br J Cancer. 2021 Jan;124(1):217-227. PubMed PMID: 33144693
  • Satyanarayan Rao, Amy Han, Alexis Zukowski, Etana Kopin, Carol Sartorius, Peter Kabos, and Srinivas Ramachandran: Mapping Transcription Factor-Nucleosome Dynamics from Plasma cfDNA. BioRxiv; doi: https://doi.org/10.1101/2021.04.14.439883
  • Abstract 2611: Transcription factor-nucleosome dynamics inferred from plasma cfDNA delineates tumor and tumor-microenvironment phenotype Satyanarayan Rao, Amy Han, Alexis Zukowski, Etana Kopin, Peter Kabos and Srinivas Ramachandran Cancer Res July 1 2021 81 (13 Supplement) 2611-2611; DOI:10.1158/1538-7445.AM2021-2611
  • Abstract 2116: Promoter enrichment of subnucleosomes using breast cancer cell-free DNA Alexis Zukowski, Amy Han, Peter Kabos and Srinivas Ramachandran Cancer Res July 1 2021 81 (13 Supplement) 2116-2116; DOI:10.1158/1538-7445.AM2021-2116
  • Abstract 2867: Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide Jennifer K. Richer, Nicole S. Spoelstra, Alyse Winchester, Julia Wulfkuhle, Sharon B. Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin and Anthony D. Elias Cancer Res July 1 2021 81 (13 Supplement) 2867-2867; DOI:10.1158/1538-7445.AM2021-2867
  • 264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC): S. Chandarlapaty1, H.M. Linden2, P. Neven3, K. Petrakova4, A. Bardia5, P. Kabos6, S. Braga7, V. Boni8, V. Pelekanou9, N. Ternès10, A. Gosselin10, M. Celanovic9, P. Cohen10, G. Paux9, M. Campone11
  • 333TiP - AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer: M. Campone1, A. Bardia2, P. Kabos3, S. Chandarlapaty4, P. Neven5, V. Boni6, S. Lord7, S. Cartot-Cotton8, M. Celanovic9, A. Gosselin8, V. Pelekanou9, H.M. Linden10
  • AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).:Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarina Petrakova, Aditya Bardia, Peter Kabos, Sofia A. D. S. Braga, Valentina Boni, Alice Gosselin, Sylvaine Cartot-Cotton, Séverine Doroumian, Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone
  • Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).: Heather M. Moore, Valentina Boni, Meritxell Bellet, Begoña Bermejo De Las Heras, Maria Gión Cortés, Catherine Oakman, Peter Schmid, Xuan Bich Trinh, Duncan Wheatley, Komal L. Jhaveri, Peter Kabos, Elgene Lim, Thierry Velu, Ciara Metcalfe, Mary R. Gates, Ching-Wei Chang, John Bond, Leonard D Goldstein, Jennifer O'Hara Lauchle, Aditya Bardia
  • P1-17-01. Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide:Jennifer Richer1, Nicole Spoelstra1, Alyse Winchester1, Julia Wulfkuhlue2, Rosa Gallagher3, Sharon Sams1, Gregory Vidal4, Peter Kabos1, Jennifer Diamond1, Elena Shagisultanova1, Anosheh Afghahi1, Jose Mayordomo1, Tessa McSpadded1, Gloria Crawford1, Virginia Borges1, Dexiang Gao1, Emanuel Petricoin1 and Anthony Elias1.
  • P1-17-11. Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer: Sarat Chandarlapaty1, Hannah M Linden2, Patrick Neven3, Katarina Petrakova4, Aditya Bardia5, Peter Kabos6, Sofia Braga7, Valentina Boni8, Alice Gosselin9, Marina Celanovic10, Patrick Cohen9, Gautier Paux10, Vasiliki Pelekanou10, Nils Ternès9, Joon Sang Lee10 and Mario Campone11
  • P1-18-26. Intracranial efficacy of tucatinib, palbociclib and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases: Elena Shagisultanova1, William Gradishar2, Ursa Brown-Glaberman3, Pavani Chalasani4, Andrew Brenner5, Alison Stopeck6, Jose Mayordomo1, Jennifer Diamond1, Peter Kabos1 and Virginia F. Borges1
  • OT2-11-03. AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-)PIK3CA-mutated advanced breast cancer: Mario Campone1, Aditya Bardia2, Peter Kabos3, Sarat Chandarlapaty4, Patrick Neven5, Valentina Boni6, Simon Lord7, Sylvaine Cartot-Cotton8, Marina Celanovic9, Alice Gosselin8, Vasiliki Pelekanou9 and Hannah M Linden10
  • OT2-11-04. Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer: Mario Campone1, Sarat Chandarlapaty2, Aditya Bardia3, Patrick Neven4, Katarina Petrakova5, Peter Kabos6, Valentina Boni7, Sofia Braga8, Marina Celanovic9, Patrick Cohen10, Alice Gosselin10, Sylvaine Cartot-Cotton10, Vasiliki Pelekanou9 and Hannah Linden11
  • P5-18-07. Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer : omas G Neilan1, Rafael Villanueva-Vázquez2, Meritxell Bellet3, Elena López-Miranda4, Laura García-Estévez5, Peter Kabos6, John Bond7, Mary R Gates7, Ching-Wei Chang7 and Valentina Boni8.
  • PD13-02. Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer:Rachel Layman1, Robert Wesolowski2, Hyo Han3, Jennifer M Specht4, Erica M Stringer-Reasor5, E. Claire Dees6, Peter Kabos7, Ingrid A Mayer8, Ulka Vaishampayan9, Janice Lu10, Keerthi Gogineni11, Aditya Bardia12, Anne F Schott13, Maysa Abu-Khalaf14, Doug Howkins15, Brian Sullivan15, Igor Gorbatchevsky15 and Hope Rugo16
  • Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater. 2020 Nov 30. [Epub ahead of print] PubMed PMID: 33257795
  • Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor breast cancer. Br J Cancer. 2020 Nov 4. [Epub ahead of print] PubMed PMID: 33144693
  • Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 Dec;9(23):8801-8808. PubMed PMID: 33063469
  • Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 Oct;59(10):1129-1139. PubMed PMID: 32822091
  • Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 Oct 15;26(20):5310-5319. PubMed PMID: 32694159
  • Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 Jun 23;22(1):68. PubMed PMID: 32576280
  • Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 Feb 27;5(4). PubMed PMID: 32045383
  • McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ß-catenin dynamics in breast cancer cells. Oncogene. 2020 Mar;39(12):2478-2492. PubMed PMID: 31988452
  • Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. PubMed PMID: 31969331
  • Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2019 Feb 28;47(4):e20. PubMed PMID: 30496484
  • Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2018 Nov 29. [Epub ahead of print] PubMed PMID: 30496484
  • Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 Aug 2;20(1):82. PubMed PMID: 30071865
  • Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 25;3(14). [Epub ahead of print] PubMed PMID: 30046001
  • Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JR. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer. Oncology (Williston Park). 2018 Jun;32(6):298-302. PubMed PMID: 29940061
  • Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers. Clin Cancer Res. 2018 May 1;24(9):2050-2059. PubMed PMID: 29066505
  • Stokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CM. Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States. Clin Breast Cancer. 2018 Jun;18(3):220-228. PubMed PMID: 28797765
  • Contreras-Zárate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, Jacobsen BM, Edgerton SM, Thor AD, Borges VF, Lillehei KO, Graner MW, Kabos P, Cittelly DM. Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. Front Oncol. 2017;7:252. PubMed PMID: 29164052
  • Banerji U, Dean E, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose HJ, Barrett JC, Carr TH, Cheung SA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates JW, Schellens JHM. A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2017 Oct 24. [Epub ahead of print] PubMed PMID: 29066505
  • Gillen AE, Brechbuhl HM, Yamamoto TM, Kline E, Pillai MM, Hesselberth JR, Kabos P. Alternative Polyadenylation of PRELID1 Regulates Mitochondrial ROS Signaling and Cancer Outcomes. Mol Cancer Res. 2017 Dec;15(12):1741-1751. PubMed PMID: 28912168
  • Stokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CM. Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States. Clin Breast Cancer. 2017 Jun 29. [Epub ahead of print] PubMed PMID: 28797765
  • Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 Dec;8(5-6):269-285. PubMed PMID: 28741260
  • Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 Sep 15;77(18):4934-4946. PubMed PMID: 28729413
  • Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017;7:94. PubMed PMID: 28555173
  • Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?. J Natl Compr Canc Netw. 2017 Apr;15(4):494-503. PubMed PMID: 28404760
  • Iyer P, Jasem J, Springer MA, Klein CE, Kabos P. PALB2-Positive Breast Cancer in a 40-Year-Old Man. Oncology (Williston Park). 2017 Jan 15;31(1):50-2, 54. PubMed PMID: 28090623
  • Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 1;23(7):1710-1721. PubMed PMID: 27702820
  • Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2016 Jun 2;35(22):2881-92. PubMed PMID: 26411365
  • Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 Jun 10;34(17):1995-2002. PubMed PMID: 27001563
  • Gillen AE, Yamamoto TM, Kline E, Hesselberth JR, Kabos P. Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics. 2016 May 5;17:338. PubMed PMID: 27150721
  • Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2016 Oct 4. [Epub ahead of print] PubMed PMID: 27702820
  • Schade H, Davis L, Kabos P. Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer. Oncology (Williston Park). 2016 Nov 15;30(11). PubMed PMID: 27854101
  • Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 Dec 15;30(12). PubMed PMID: 27987198
  • Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 Dec;35(4):547-573. PubMed PMID: 28025748
  • Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun. 2015 Dec 21;6:10077. PubMed PMID: 26687066
  • Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2015 Sep 28. [Epub ahead of print] PubMed PMID: 26411365
  • Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep;29(9):669-70, 678-9. PubMed PMID: 26384804
  • Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May;14(5):1117-29. PubMed PMID: 25758253
  • Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul;34(28):3676-87. PubMed PMID: 25241899
  • Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Feb 3. [Epub ahead of print] PubMed PMID: 24497407
  • Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR, Pillai MM. Genome-Wide Analysis of miRNA-mRNA Interactions in Marrow Stromal Cells. Stem Cells. 2014 Mar;32(3):662-73. PubMed PMID: 24038734
  • Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2014 Sep 22;0. [Epub ahead of print] PubMed PMID: 25241899
  • Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV. Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery. Curr Chem Genomics Transl Med. 2014;8(Suppl 1):27-35. PubMed PMID: 24596682
  • Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR, Pillai MM. Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. Stem Cells. 2014 Mar;32(3):662-73. PubMed PMID: 24038734
  • Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb;4(1):36-49. PubMed PMID: 23184698
View All (70 Total) View Less

Practice Locations

Diane O'Connor Thompson Breast Center - Anschutz
1635 Aurora Ct
3rd Floor
Aurora, CO 80045
720-848-1030

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (2006)
  • Medical Oncology, Board Certification (2009)
Conditions & Treatments
  • Cancers - Breast Cancer
  • Cancers
Clinical Interests
Breast Cancer

General Information

Medical Schools:
  • MD, Comenius University School of Medicine (1998)
Internships:
  • University of Southern California/California Hospital Medical Center (Los Angeles) Program (2004)
Residency Programs:
  • University of Southern California/California Hospital Medical Center (Los Angeles) Program, Internal Medicine (2006)
Fellowships:
  • University of Colorado (University Hospital) Program, Hematology and Oncology (2009)
Languages: English
Department: Medicine-Medical Oncology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;